BICX - BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors | Benzinga
ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.
Dr. DeVarney spearheaded the development of Probuphine® (buprenorphine implant), the first six-month, subcutaneous implant approved in the United States, Canada, and Europe for the treatment of opioid use disorder. Dr. DeVarney is the President, Chief Operating Officer, and a Director of Titan Pharmaceuticals, Inc. She was previously Titan's Chief Scientific Officer and has been with the company since 2007. During her tenure with Titan, Dr. DeVarney has been awarded and served as the Principal Investigator on multiple research grants funded by the National Institute on Drug Abuse (NIDA), and currently serves as an advisor on the National Advisory Committee on Drug Abuse (NACDA). Before joining Titan, she served as Senior Medical Director at Corcept Therapeutics, Inc. and as Senior Medical Director for Neurosciences within World Wide Human Health at Merck & Co. Dr. DeVarney also held positions within the neurosciences research, development, and medical affairs organizations of SmithKline Beecham and GlaxoSmithKline. Throughout her academic and industry careers, Dr. DeVarney's research has focused primarily on substance use disorders, neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease, mood and anxiety disorders as well as metabolic disorders and obesity. Her research has been published in peer-reviewed medical journals such as The American Journal of Psychiatry, Drug and Alcohol Dependence, The Journal of the American Medical Association, and Addiction. She has also presented extensively at the American Psychiatric Association, the American College of Neuropsychopharmacology, the American Society of Addiction Medicine, and the International Society of Addiction Medicine.
Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, "We are honored and excited to welcome Dr. DeVarney to the BioCorRx Pharmaceuticals board. Dr. DeVarney has 28 years of experience as a neuroscientist in ...